<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>Gary Rabin &#124; Advanced Cell Technology &#124; Chairmans Blog</title>
	<link>http://www.thechairmansblog.com/gary-rabin</link>
	<description>Mr. Gary Rabin serves as Interim Chairman and Chief Executive Officer of Advanced Cell Technologyand has a 30-year management career working with emerging technologies and restructuring distressed corporate environments.</description>
	<lastBuildDate>Thu, 16 Feb 2012 20:09:41 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.0" -->

	<item>
		<title>Timing and Pace of Our Clinical Trials</title>
		<description><![CDATA[ 
  
Greetings,
As you are undoubtedly aware, last July we initiated the first-ever clinical trials using a cell therapy derived from human embryonic stem cells (hESCs) to treat various forms of macular degeneration.  The end goal for our clinical trials is to test whether or not the retinal pigment epithelial (RPE) cells we make [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2012-02/timing-and-pace-of-our-clinical-trial.html</link>
			</item>
	<item>
		<title>Clinical Trials, Results, and Timing</title>
		<description><![CDATA[Greetings,
For many of us, the New Year is a time not just for looking forward but for reflecting on events, achievements and lessons learned over the past year.  I anticipate an amazing year ahead for ACT, and at the same time I also cannot help but reflect with pride on how far the company [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2012-01/clinical-trials-results-and-timing.html</link>
			</item>
	<item>
		<title>Settlements, Proxy, and Looking Ahead</title>
		<description><![CDATA[
Greetings,
You have no doubt seen our recent 8K filing and press release about the settlements and the filing of the preliminary proxy.  In this blog post I would like to add a bit of color on these topics and also touch on other recent milestones, plans for the future, and give a run-down of our [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-12/settlements-proxy-and-looking-ahead.html</link>
			</item>
	<item>
		<title>Reflecting on the EU Court Ruling: A Setback for European ESC Field, But Not for ACT</title>
		<description><![CDATA[Greetings,
As you may have heard in the news, or read about in the press release we issued, the European Court of Justice just ruled that inventions based on the use of human embryonic stem cells (hESCs) for scientific research cannot be patented, when the process of deriving those cells destroys embryos.
This ruling is most unfortunate, [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-10/reflecting-on-the-eu-court-ruling-a-setback-for-european-esc-field-but-not-for-act.html</link>
			</item>
	<item>
		<title>ACT’s Director of Regulatory Affairs Edmund Mickunas to Present at Phacilitate Cell &amp; Gene Therapy Forum in Singapore; Reflects Growing Interest in Company and Its Programs in East Asia</title>
		<description><![CDATA[Greetings,
ACT’s Director of Regulatory Affairs, Edmund “Ed” Mickunas, will be presenting on the company’s behalf at a major industry conference, the “Phacilitate Cell &#038; Gene Therapy Forum Asia 2011,” Sept. 19-21, in Singapore.
Ed’s presentation will focus on regulatory issues surrounding  human clinical trials in the field of regenerative medicine, such as our two recently-initiated [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-09/act%e2%80%99s-director-of-regulatory-affairs-edmund-mickunas-to-present-at-phacilitate-cell-reflects-growing-interest-in-company-and-its-programs-in-east-asia.html</link>
			</item>
	<item>
		<title>Supporting the Federal Court Ruling Allowing Federal Funding of Embryonic Stem Cell Research</title>
		<description><![CDATA[Greetings,
You have probably seen the news that yesterday U.S. District Judge Royce Lamberth ruled that the National Institutes of Health (NIH) guidelines on embryonic stem cell research do not violate federal law, and that he in turn dismissed the legal challenge to such funding that was initiated last year.
ACT is not and never has been [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-07/supporting-the-federal-court-ruling-allowing-federal-funding-of-embryonic-stem-cell-research.html</link>
			</item>
	<item>
		<title>Quick Update and Major Upcoming Milestones</title>
		<description><![CDATA[Greetings,
We are very pleased to update you on our latest progress and some significant upcoming milestones.
As you may know, we recently announced that ACT was granted EU orphan medicinal product designation for our retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for the treatment of Stargardt’s Macular Dystrophy (SMD).
Additionally, we also [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-06/quick-update-and-major-upcoming-milestones.html</link>
			</item>
	<item>
		<title>Time Magazine Features ACT’s Clinical Trials For Macular Degeneration</title>
		<description><![CDATA[Greetings,
As you are no doubt aware, last Thursday, June 16th, we announced that the first patients have been enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) for our two upcoming Phase 1/2 clinical trials using using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-06/time-magazine-features-acts-clinical-trials-for-macular-degeneration.html</link>
			</item>
	<item>
		<title>Getting to Know ACT’s New Online Home</title>
		<description><![CDATA[Greetings,
As you know, Advanced Cell Technology is evolving very quickly.  The past year has been marked by the achievement of numerous long-term milestones, the most significant of which is our progress in moving the retinal pigment epithelial (RPE) program forward toward the clinic.  We are currently enrolling patients for our Phase 1/2 human clinical trials [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-05/getting-to-know-act%e2%80%99s-new-online-home.html</link>
			</item>
	<item>
		<title>ACT Retains Top Life Sciences PR/Corporate Communications Firm, Russo Partners</title>
		<description><![CDATA[Greetings,
As you are no doubt aware, ACT is quickly evolving from a development-stage biotechnology company to a clinical-stage company developing  regenerative medicine.  We now have two of the three total FDA clearances for embryonic stem cell-based clinical trials that have ever been issued, and we are eagerly anticipating starting these trials in the [...]]]></description>
		<link>http://www.thechairmansblog.com/gary-rabin/2011-02/act-retains-top-life-sciences-prcorporate-communications-firm-russo-partners.html</link>
			</item>
</channel>
</rss>

